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Background: Respiratory viruses have become increasingly recognised as important agents in pulmonary exacerbations in infants and children
with CF. The aim of this study was to determine the prevalence of respiratory viruses during acute pulmonary exacerbations in adults and compare
the severity of these exacerbations with non-viral associated exacerbations.
Methods: This was a retrospective case control study. Viral throat swabs were taken from all patients presenting with an acute pulmonary
exacerbation requiring intravenous antibiotic treatment over a 12 month period.
Results: There were 432 pulmonary exacerbations in 180 adults. A positive viral PCR in 42 exacerbations indicated a prevalence of 9.7%. The
commonest virus isolated was rhinovirus (n = 29, 69%) with inﬂuenza A/H1N1 in seven patients (16.7%). Exacerbations associated with a
positive viral PCR had a greater fall in lung function at presentation with higher levels of inﬂammatory markers. They received more days of
intravenous antibiotics, showed less response to treatment and had a shorter time to next pulmonary exacerbation compared to matched controls.
Conclusion: Viral associated pulmonary exacerbations in adults with CF are associated with more severe pulmonary involvement and respond less
well to standard treatment.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Respiratory viruses; Pulmonary exacerbation; Polymerase chain reaction; Rhinovirus1. Introduction
Pulmonary exacerbations in people with cystic fibrosis (CF)
accelerate deterioration of lung function and cause increased
morbidity and mortality [1]. Respiratory viral infections are
a major trigger of acute pulmonary exacerbations in infants,
children and adults with CF. Although studies differ in the viral
detection methods used, the incidence of respiratory viruses in
children with CF is similar to that of healthy peers [2–5], but
the severity of the clinical illness associatedwith infection has been
shown to be greater in CF with an increased risk of hospitalisation,
longer duration of treatment and more severe course of disease
[2,4–10].⁎ Corresponding author. Tel.: +44 7802591611; fax: +44 113 2066048.
E-mail address: christine.etherington@leedsth.nhs.uk (C. Etherington).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.06.004In early studies, viruses were identified in up 28% of CF related
pulmonary exacerbations [2,3,9,11,12], although Armstrong et al.
reported a much higher prevalence of 52% in younger patients
[13]. In adults, a 10 year retrospective study reported the prev-
alence of viral isolation during a pulmonary exacerbation to
be significantly lower at 5.1% [14]. These earlier studies, using
immunofluorescence, culture and serology methodology, and
screening for only a limited number of viruses, are likely to have
significantly underestimated the prevalence of viral infections.
Multiplex real-time polymerase chain reaction (PCR) allows
detection of viruses within 24 hours and has a greater sensitivity
and specificity than the older techniques [15]. More recent studies
using PCR for viral detection have reported prevalence rates of
45–60%, mainly in children [8–10,16]. The majority of studies
to date have been in infants and children with CF; few have
addressed the frequency and clinical impact of viral associated
exacerbations in adults.by Elsevier B.V. All rights reserved.
Table 1
Baseline demographic data.
Viral group
(n = 42)
Matched controls
(n = 42)
p Value
Age (years) 26.5 (22.8–30.3) 29 (24.8–33) p = 0.225
Male 16/42 (38%) 16/42 (38%) p = 0.995
CFRD 14/42 (33%) 18/42 (42%) p = 0.040
Enteral tube feeding a 17/42 (40.5%) 8/42 (19%) p = 0.032
Chronic Pseudomonas b 32/42 (76%) 32/42 (76%) p = 0.998
p.Phe508del/p.Phe508del 28/42 (67%) 27/42 (64%) p = 0.877
‘Best’ weight (kg) 56.3 (49.4–66.7) 59.2 (54.9–67.4) p = 0.072
‘Best’ BMI (kg/m2) 21.5 (19.7–23.5) 21.4 (19.9–23.4) p = 0.855
‘Best’ FEV1 (% predicted) 49 (41–66.3) 50.5 (40.1–67.8) p = 0.727
‘Best’ FVC (% predicted) 68.5 (58.2–85.3) 71.5 (57.8–83) p = 0.968
‘Best’ FEV1 (L) 1.6 (1.3–2.1) 1.7 (1.4–2.3) p = 0.625
‘Best’ FVC (L) 2.6 (2.1–3.2) 2.7 (2.3–3.4) p = 0.455
Data are presented as median (IQR) or proportion (%).
CFRD: Cystic Fibrosis Related Diabetes; FEV1: Forced expiratory volume in one
second; FVC: Forced vital capacity; L: Litres; % predicted: Percentage predicted
of normal; BMI: Body Mass Index.
a Nasogastric or gastrostomy feeding.
b Using the Leeds Criteria for Pseudomonas status [17].
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of respiratory viruses in adult patients treated with intravenous
antibiotics for an acute pulmonary exacerbation and to compare
the severity of these exacerbations with non-viral associated
exacerbations. A secondary aim was to determine the impact of
influenza A/H1N1 isolation during the 2009 pandemic in a large
adult CF population.
2. Materials and methods
2.1. Study subjects
This was a retrospective case control study in adult patients
attending the Leeds Regional Adult CF Unit who were com-
menced on treatment with intravenous antibiotics for an acute
pulmonary exacerbation over a 12 month period between
01/12/2008 and 30/11/2009. Patients required an established
diagnosis of CF (sweat chloride N60 mmol/L or genotype
known to cause the disease). Patients with CF who had under-
gone lung transplantation were excluded from the study. Ethical
approval was obtained from Leeds Central Ethics Committee.
The control group consisted of patients who were treated with
intravenous antibiotics for an acute pulmonary exacerbation during
the study period who had a negative viral throat swab result.
Patients with a positive viral PCR result were matched to control
patients according to gender, age, genotype, Pseudomonas status
[17] and their ‘best’ BMI and FEV1 percentage predicted in the
12 month period preceding the exacerbation.
2.2. Collection of clinical information and specimens
Throat swabs were taken for viral PCR at the start of a course
of intravenous antibiotic treatment for an acute pulmonary exac-
erbation. Patients from whom the influenza A/H1N1 virus was
isolated were prescribed additional treatment with Oseltamivir.
Throat swabs were analysed using the MBNTP 50 Respiratory
Virus multiplex PCR M assay in supplement with the HPA PCR
methods for influenza. This multiplex PCR provides a qualitative
detection of parainfluenza (types 1–4), influenza, adenovirus,
metapneumovirus, rhinovirus and respiratory syncytial virus. The
respiratory multiplex PCR uses 8 different 5′ hydrolysis probes
with 4 different fluorophore labels. Successful amplification of
RNA is checked for by MS2 phage RNA amplification [15].
Demographic and clinical data were obtained from an elec-
tronic patient record (EPR) system (EMIS®) including the
specific virus isolated, number of days of intravenous antibiotic
treatment, time to next pulmonary exacerbation and days of
intravenous antibiotics required 12 months pre and post the
index exacerbation. Inflammatory markers (C-reactive protein
[CRP], peripheral blood white cell count [WCC] and neutrophil
count), weight, body mass index (BMI) and lung function (forced
expiratory volume in one second [FEV1] and forced vital capacity
[FVC] absolute value and percentage predicted) were measured
at the start and end of treatment.
The patients’ ‘best’ weight, BMI and lung function values
in the 12 months preceding the exacerbation and three to
six months following the exacerbation were obtained. Lungfunction was measured using a Vitalograph 2120 with
European Respiratory Society criteria used to calculate the
percentage predicted values. The spirometer was calibrated on a
daily basis. Weight was measured on electronic weight scales
which were calibrated on a monthly basis.
2.3. Statistical analysis
Data are presented as median and interquartile range (IQR)
for metric variables and proportion (%) for categorical variables.
The results of the studied groups (medians) were compared using
Mann–Whitney U test. Proportions were compared using Chi
squared test (χ2). Wilcoxon Signed Rank test was used to com-
pare paired data. A p value of b0.05 was considered significant.
Statistical analysis was performed using Minitab, version 14.0.
3. Results
3.1. Prevalence of viral isolation
A total of 432 pulmonary exacerbations in 180 patients were
identified during the study period. Respiratory viruses were
isolated at presentation in 42 courses of treatment in 42
patients, with a prevalence of 9.7%. Twenty-nine (69%) of the
42 patients were positive for rhinovirus and seven (16.7%) for
influenza A/H1N, with the highest prevalence of viral isolates
seen between the months of September and November. Five
patients (11.9%) had other viruses isolated (2 parainfluenza,
1 respiratory syncytial virus (RSV), 1 metapneumovirus and
1 influenza B) and one patient (2.4%) isolated both adenovirus
and rhinovirus from the same throat swab sample.
3.2. Population characteristics
Forty-two patients with a positive viral PCR were matched
with forty-two control patients (Table 1). The viral group had
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Fig. 1. Comparison of lung function (Median FEV1% predicted); viral vs. matched
controls.
Table 3
Percentage and absolute change (Δ) in pulmonary function following intravenous
antibiotic treatment.
Viral group Matched controls p Value
Δ FEV1 (% pred.) 2% (0 to 8) 6.5% (1.8 to 11.3) p = 0.043
Δ FEV1 (L) 0.1 L (0 to 0.3) 0.2 L (0.1 to 0.4) p = 0.071
Δ FVC (% pred.) 0% (−3 to 12.2) 7% (0 to 16) p = 0.040
Δ FVC (L) 0 L (−0.1 to 0.6) 0.3 L (0 to 0.6) p = 0.225
Data presented as median (IQR).
FEV1: Forced expiratory volume in one second; L: Litres; % predicted: percentage
predicted of normal; FVC: Forced vital capacity.
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Diabetes (CFRD) and higher number of patients receiving
overnight enteral tube feeding; however there was no sig-
nificant difference in weight or BMI between the two groups.
Patients with a viral associated exacerbation were treated with
intravenous antibiotics for a significantly longer period of time
compared to matched controls; median (IQR) number of days
18 (14–24) vs. 15 (14–15), p = 0.022. The number of days of
intravenous treatment the patients received was based on the
treating physician's assessment of their response to treatment.
3.3. Comparison of pulmonary function
Patients with a viral associated exacerbation had a greater
fall in lung function at the start of treatment (Fig. 1). The
matched control group showed a significant improvement in
median FEV1 percent predicted values between start and end of
treatment which was not seen in patients with a viral associated
exacerbation (Table 2). There was also a significant difference
between the percentage change in FEV1 and FVC predicted
values between the two groups following intravenous antibiotic
treatment (Table 3). In patients with a viral associated exac-
erbation, both end and follow up median FEV1 (IQR) values
[38 (32.5–52%) and 40.5 (34–52%) predicted respectively]
were significantly lower than their ‘best’ value [49 (41–66.3%)
predicted, p = 0.039). In the matched control group, the medianTable 2
Pulmonary function at start and end of treatment.
Start treatment End treatment p Value
FEV1 (% predicted) V 35 (27.0–44.5) V 38 (32.5–52.0) p = 0.176
MC 41 (30–52) MC 48 (35–66) p = 0.040
FEV1 (L) V 1.2 (0.9–1.5) V 1.3 (0.9–1.7) p = 0.255
MC 1.4 (0.9–1.7) MC 1.6 (1.2–2.2) p = 0.172
FVC (% predicted) V 52.5 (43.0–61.5) V 55 (45.5–69.0) p = 0.168
MC 55.5 (46.3–74) MC 67 (52–82) p = 0.048
FVC (L) V 1.9 (1.6–2.5) V 2.2 (1.7–2.7) p = 0.103
MC 2.2 (1.8–2.9) MC 2.7 (2.0–3.3) p = 0.099
Data presented as median (IQR) V = viral group, MC = matched control group.
FEV1: Forced expiratory volume in one second; L: Litres; % predicted: percentage
predicted of normal; FVC: Forced vital capacity.(IQR) FEV1 value at the end of treatment was not significantly
different from the ‘best’ values in the preceding 12 months
[48 (35–66%) vs. 50.5 (40.1–67.8%) predicted, p = 0.965]
and was maintained at follow up [47.5 (36.8–63%) predicted]
(Fig. 1).3.4. Inflammatory markers, weight and exacerbation frequency
There was a median (IQR) weight increase of 0.6 (−0.4 to
1.5) kg and weight loss of 0.1 (−1.1 to 0.6) kg in the control
and positive viral PCR groups respectively, p = 0.015. Patients
with a viral associated exacerbation had a significantly higher
CRP and neutrophil count at the start of treatment when com-
pared to the matched control group (Table 4). In addition,
the end of treatment CRP remained significantly higher than
in the matched control group. The time to the next pulmonary
exacerbation was significantly shorter in patients with a viral
associated exacerbation [64 (24–115) days] compared to the
control group [107 (67–199) days] (p b 0.001). The number
of days of intravenous antibiotics the patients received in the
12 months after the index exacerbation was significantly greater
in patients with a viral associated exacerbation [63 (40–99) days]
compared to matched controls [28 (14–71) days] (p b 0.001).
Although the patients were matched in terms of their ‘best’ FEV1
percent predicted value in the 12 months preceding the index
exacerbation, those with a subsequent viral associated exac-
erbation had received more days of intravenous antibiotic
therapy [39 (40–83) days] compared to the matched control
group [29 (14–52) days], however the difference was not
statistically significant (p = 0.061).Table 4
Inflammatory markers at start and end of intravenous antibiotic treatment.
Viral group Matched controls p Value
Start CRP (mg/L) 26 (15.3–81) 12.7 (5–25) p = 0.001
Start WCC (×109/L) 11.3 (8.6–13.9) 10 (7.7–12.8) p = 0.102
Start Neutrophil (×109/L) 9 (6.5–11.2) 6.9 (4.9–9.5) p = 0.032
End CRP (mg/L) 11.4 (5–19.3) 5 (5–6.1) p = 0.002
End WCC (×109/L) 8.7 (7.2–12.1) 8.5 (7.3–10.8) p = 0.774
End Neutrophil (×109/L) 6.2 (4.5–9.4) 5.5 (4.3–7.2) p = 0.676
Data presented as median (IQR).
CRP: C-reactive protein; WCC: white cell count.
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There were no significant differences in the clinical outcome
measures between rhinovirus associated exacerbations and those
associated with other viruses. The number of days of intravenous
antibiotic treatment, inflammatory markers, lung function and
weight were similar in both groups. In particular there were no
differences in the outcome following influenza A/H1N1 infection
when compared to other viral associated exacerbations, although
the numbers in this group were small.
4. Discussion
The results show that adult patients with a viral associated
pulmonary exacerbation had a greater fall in lung function
at start of treatment, a heightened inflammatory response and
worse clinical outcome compared to matched controls. They
received significantly more days of intravenous antibiotic treat-
ment and had a shorter time to the next exacerbation. In both
children and adults with CF, respiratory viral infections have
been increasingly recognised as a major trigger for pulmonary
exacerbations and are associated with an increased risk of
hospitalisation, short and long term pulmonary morbidity and
disease progression. It is well documented that respiratory viral
infections predispose patients to secondary bacterial coloni-
sation and infection [11]. Previous studies reported the link
between viral associated exacerbations and more severe pul-
monary deterioration, but these have been predominantly in
infants and children with CF [2,4,5,12,13].
The damaging effects of respiratory viral infection in other
patient cohorts are well recognised. Respiratory viral infections
have been identified as a significant cause of morbidity in infants,
the elderly and the immunocompromised. Between 80% and
85% of asthma exacerbations in children are thought to be viral
mediated, with rhinovirus being the most prevalent [18]. The
human rhinoviruses are the most common cause of colds and
influenza-like illnesses and have significant impact on patients
with underlying respiratory disease. In adult patients hospitalised
with near-fatal asthma (n = 17), acute exacerbations of asthma
(n = 29) or chronic obstructive pulmonary disease (n = 14),
there was a similar proportion of virus positive patients during the
acute phase (59%, 41% and 64% respectively). Quiescent-phase
specimens were examined from patients who were initially virus
positive. Viral nucleic acids were detected in 52% (31/60) of
acute-phase specimens and 7% (2/29) of quiescent-phase speci-
mens examined, (p b 0.001), [19].
Our results demonstrated a seasonal variation of respiratory
virus isolation with rhinovirus and influenza A/H1N1 peaking
between the months of September and November. Community
based studies have characterised the seasonality and clinical
features of viral respiratory tract infections, with rhinovirus
isolation occurring in a distinct and consistent seasonal pattern
[20]. In patients with CF, viral associated respiratory infections
during the winter months have been reported to be closely
associated with initial isolation and chronic colonisation with
Pseudomonas aeruginosa [21]. In addition, Ortiz et al. examined
the relationship between the incidence of pulmonary exacerbationsand the influenza virus season using data from the CF Foundation
Patient Registry [22]. They estimated an excess of 147.6 pul-
monary exacerbations per 10,000 people with CF (2.1% of total
number of exacerbations) that were attributable to influenza every
year, demonstrating a substantial contribution of the influenza
season to CF morbidity.
In the present study rhinovirus was by far the most common
virus isolated, accounting for 69% of all detected viruses. Several
other studies report human rhinoviruses as the predominant
pathogens in pulmonary exacerbations in CF [7–9,16]. In other
respiratory diseases such as asthma, rhinovirus has also been
found to be the commonest viral pathogen, accounting for ap-
proximately 80% of viral triggered exacerbations [18]. For a long
time it was assumed that rhinoviruses were restricted to the upper
airways, but advances in molecular diagnosis have shown that
they have the ability to infect the lower respiratory tract [23]. In
children with CF, rhinovirus infection is associated with signif-
icant acute morbidity (increased cough and sputum production,
nasal congestion and wheeze), [9]. More recently, rhinovirus
subtypes A2 and C have been linked with an increased frequency
of respiratory exacerbations and disease severity in children with
CF [24].
The present study was carried out in a large adult population
with CF who had undergone prospective viral screening since
2007. As part of routine practice, all adult patients commencing
on intravenous antibiotic treatment for a pulmonary exacerba-
tion have been screened for respiratory viruses (throat swabs)
using PCR at the start of treatment. The prevalence of viral
isolation using molecular detection methods in this adult study
was 9.7%, which is significantly lower than that reported in
infants and children with CF [8–10]. Respiratory viral infections
however are known to be significantly more prevalent in infants
and young children due to the abundance of circulating viruses
and their ease in transmission among hosts. More recently, Wark
et al. reported prevalence data for 17 adults with CF; a virus was
isolated by PCR in 52% of presentations with either increased
chest symptoms or coryzal symptoms and was associated with
68% of acute pulmonary exacerbations [16]. In patients who did
exacerbate, viral isolation was not associated with a greater fall in
lung function at presentation, in contrast to our findings. Patient
numbers were however significantly lower than in the present
study and not all the exacerbations were treated with intravenous
antibiotics.
The second commonest virus isolated in our study was
influenza A/H1N1. When compared to other viral associated
exacerbations, influenza A/H1N1 isolation did not impact more
negatively on clinical status in terms of lung function, inflam-
matory markers or duration of treatment. This may reflect the
early use of Oseltamivir in these patients, according to contem-
poraneous national guidelines. Recent studies investigating the
impact of influenza A/H1N1 in patients with CF are conflicting.
Nash et al. described a good outcome with mild illness and
no increase in morbidity [25]. In contrast, a multicentre cohort
study reported three deaths due to respiratory failure in patients
with severe pulmonary disease [26]. None of these patients had
been vaccinated and all had received antiviral therapy. A large
European web based study reported transient but significant
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isolation [27]. Only 8.8% of the study population however had
been vaccinated. Whilst most of the patients recovered and their
FEV1 one month after the infection was similar to that before
the infection, five patients required mechanical ventilation and
three patients with severe respiratory disease died.
There are several hypotheses to explain the enhanced effect
of respiratory viral infections in people with CF [28,29]. Some
authors report a heightened inflammatory response including
activation of nuclear factor (NF)-kb, generation of pro-
inflammatory cytokines and chemokines, increased mucus pro-
duction and bronchial hyper-responsiveness [29,30]. Another
postulated mechanism is deficiency in the antiviral innate
immune response in CF cells leading to higher viral replication.
Increased viral replication might explain the more severe and
prolonged symptoms seen during viral associated exacerbations
in CF patients compared to controls. Reduced production of
nitric oxide synthetase 2 (NOS2) is one of the possible causes
of increased viral replication and persistence. NOS2 is required
for the production of nitric oxide which has potent antiviral
effects [31]. Furthermore, studies in CF indicate an indirect role
of respiratory viruses through interaction with other pathogenic
bacteria. Co-infection with bacteria and viruses is likely to be
more common in people with CF. Johansen et al. reported that
66% of patients contracted their first colonisation and 68%
chronic infection of Pseudomonas aeruginosa during the viral
season and this predominately occurred within three weeks
following a viral upper respiratory tract infection [21]. The
author concluded that viral respiratory tract infection may
“pave the way” for colonisation and chronic infection with
Pseudomonas aeruginosa. The strongest association between a
viral infection and a rise in Pseudomonas antibody levels was
found by Peterson et al.; 20% of all patients who developed
chronic Pseudomonas colonisation had a previous RSV
infection compared to 7% who did not, (p b 0.05), [11].
There is increasing evidence that interactions between bacteria and
viruses influence the host immune response. Several strains of
Pseudomonas show increased adherence to damaged airway
epithelial cells in the presence of RSV, which suggests that RSV
can act as a coupling agent between bacteria and host cells [32].
Recently, deficient virus control of the CF airway epithelium due to
impaired induction of antiviral mediators including type I and III
interferons has been demonstrated in vitro and may explain the
increased susceptibility of patients with CF towards rhinoviruses
and increased rhinovirus replication [33].
Our results emphasise the need for strict isolation protocols
and preventative strategies to reduce the pulmonary morbidity
and mortality associated with viral associated exacerbations
in people with CF. Influenza vaccination is recommended
annually for CF patients aged ≥6 months and their family
members [34]. It is not recommended in those younger than
6 months due to poor immunogenicity. Immunisation against
Influenza A virus has been shown to provoke an adequate
antibody response in patients with CF [35]. A Cochrane review
of four randomised trials comparing any influenza vaccine with
placebo or with another type of influenza vaccine in CF did not
show any clinical benefit [36]. A more recent study however,compared influenza infection rates between 41 vaccinated and
22 non-vaccinated patients with CF [37]. There was only one
influenza virus isolation in the vaccinated group compared to
four in the non-vaccinated group (p = 0.046), confirming the
anticipated protective effect. There remains a need for a well
designed adequately powered clinical trial to assess the effect-
iveness of influenza vaccination in people with CF.
Only one adult in this study isolated RSV (2.4%). In
contrast, earlier studies in infants and children with CF have
reported RSV as a predominant viral pathogen. Patients who
isolated RSV had an increased risk of lower respiratory tract
infection, prolonged hospitalisation and significant pulmonary
morbidity [4,11,13]. Currently no RSV vaccine is available.
There is considerable interest in the use of palivizumab, a
monoclonal antibody to RSV, which provides passive immu-
noprophylaxis. It is however very expensive; a survey by
McCormick et al. reported that 22 infants needed to be treated
to prevent just one hospital admission [38]. A recent Cochrane
review concluded that the strength of current evidence in CF
was insufficient to allow any conclusions regarding the efficacy
and safety of palivizumab prophylaxis in children to be made
[39].
In keeping with previously reported studies, human rhi-
noviruses were by far the most frequent respiratory viruses
isolated in the current study. With increasing evidence that
rhinovirus infection in patients with CF can lead to more severe
disease involving the lower airways with a significant impact
on pulmonary morbidity, patient quality of life and healthcare
related costs, prevention using vaccination would seem be the
most effective way of controlling virus induced diseases. As
yet however, no vaccine is available; with over 100 different
serotypes it is difficult to identify the most important sero-
types which need to be covered by a possible vaccine [40,41].
Although progress has been made, no clinically effective
rhinovirus vaccine is on the horizon yet. Recently Vareille et al.
demonstrated defective interferon I and III production as a
key pathophysiological mechanism leading to impaired virus
control by the CF airway epithelium, highlighting the potential
therapeutic benefit of interferon therapy for rhinovirus associ-
ated exacerbations [33].
The present study however has several limitations. Although
clinical, biochemical and viral throat swab data were automat-
ically collected via the electronic patient management system
at the time of presentation, this was a retrospective study.
Furthermore, viral throat swabs were only undertaken on
patients who presented with a pulmonary exacerbation requiring
treatment with intravenous antibiotics, which may explain the
lower prevalence seen in the current study. We do not have data
on the prevalence of viral isolation in adults who experienced a
self-limiting viral illness not experiencing a pulmonary exacer-
bation or those with a mild pulmonary exacerbation which
responded to oral antibiotics. In addition, some of the viral PCR
results may have been incidental findings; we do not have data as
to number with symptoms suggestive of a viral illness. Despite
the use of pulmonary exacerbations as an outcome measure in CF
trials, there is no currently acceptable definition of a pulmonary
exacerbation or indeed a standard approach to best treatment. The
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symptoms and/or reduction in lung function which had not
responded to oral antibiotic therapy. The physician's assessment
of response to treatment determined the number of days of
intravenous antibiotics the patient received during the study
period. The time to next exacerbation was also included in the
current study as a clinical outcome measure. There can however
be many reasons why people with CF have a re-admission in a
short period of time and it may not be a new exacerbation but an
incompletely treated event. It may also be influenced by the
severity of the initial exacerbation. A longitudinal study which
documents decline in FEV1 over time and comprehensively
evaluates patients for both viral and bacterial infections during
exacerbations may thus help to clarify the contribution of respi-
ratory viruses to progressive lung damage. Finally, the choice
of controls for a case control study is crucial to interpretation
of the results and in order to ascertain whether respiratory virus
associated exacerbations are more severe or require longer
therapy than those without, the cases and controls should differ
only by the presence of virus on clinical specimens. In addition
to matching on gender, age, genotype and Pseudomonas status
[17], the controls were matched on the basis of their ‘best’ BMI
and FEV1 percent predicted in the preceding 12 month period.
However, when analysing their exacerbations during this period
the viral group had received more days of intravenous antibiotics
compared to the control group. This difference however was not
significant, and thus does not suggest that those who presented
with a viral associated exacerbation had more severe underlying
disease.
Despite these limitations, this is the largest study to date to
assess the prevalence and severity of viral associated exacer-
bations in an adult population. The data demonstrate that adults
who present with a viral associated pulmonary exacerbation
are more severely unwell at presentation with a heightened
inflammatory response, require a longer course of intravenous
antibiotic therapy and respond less well to standard therapeutic
interventions. Influenza A/H1N1 isolation in this study was
not associated with a worse clinical outcome. Further work is
needed to both understand the pathogenesis of viral infection in
CF and to develop new strategies and treatments for the future.
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